Lloyds Engineering Works Limited Corrigendum Issued for First and Final Call on Rights Equity Shares

Lloyds Engineering Works Limited has issued a Corrigendum to the Notice of the First and Final Call on its partly paid-up equity shares. Due to technical reasons, the payment schedule has been revised. The call money payment period, previously set for March 31, 2026, will now open on Wednesday, February 18, 2026, and close on Wednesday, March 4, 2026. The amount due is ₹1 per share (including a premium of ₹15.50).

Revision in Rights Issue Payment Schedule

Lloyds Engineering Works Limited announced that its Rights Issue Committee approved a Corrigendum to the Notice of First and Final Call concerning its partly paid-up equity shares, following a meeting held on February 17, 2026. This revision modifies the previously announced payment timeline established in the Letter of Offer dated April 19, 2025.

Details of the Rights Issue Call

The original schedule indicated that the remaining 50% of the issue price was proposed to be called on or before March 31, 2026. The total amount payable now relates to 30,85,17,476 partly paid-up equity shares.

  • Amount Payable per Share: ₹1 per equity share (which includes a premium of ₹15.50 per share).
  • Face Value: ₹0.50 per equity share.

Revised Call Money Payment Period

Owing to certain technical adjustments, the company has finalized a new payment window for the First and Final Call:

The call money payment period will commence on Wednesday, February 18, 2026, and will conclude on Wednesday, March 4, 2026 (both dates inclusive).

Record Date Confirmation

The Corrigendum notice will be emailed to all eligible Equity Shareholders holding partly paid-up Rights Equity Shares as recorded on the Record Date, January 28, 2026. The meeting where these changes were approved commenced at 1:00 p.m. (IST) and concluded at 3:00 p.m. (IST) on the date of the announcement.

Source: BSE

Previous Article

Bank of India Notice for Call Option Exercise on Additional Tier I Bonds Series VII

Next Article

Strides Pharma Science Completes Acquisition of Neviton Softech, Making it Wholly Owned Subsidiary